Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Buy” by Brokerages

Xencor, Inc. (NASDAQ:XNCR) has been assigned an average rating of “Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $35.38.

Several brokerages have commented on XNCR. BTIG Research decreased their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, April 16th. Royal Bank of Canada lowered their price objective on shares of Xencor from $32.00 to $31.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th. Wedbush restated an “outperform” rating and issued a $34.00 target price (down previously from $36.00) on shares of Xencor in a report on Thursday, June 13th. StockNews.com raised Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 9th. Finally, BMO Capital Markets dropped their price target on Xencor from $34.00 to $32.00 and set an “outperform” rating on the stock in a research report on Friday, June 14th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Xencor during the 1st quarter valued at about $4,608,000. Silvercrest Asset Management Group LLC lifted its stake in Xencor by 4.6% in the first quarter. Silvercrest Asset Management Group LLC now owns 144,235 shares of the biopharmaceutical company’s stock valued at $3,192,000 after acquiring an additional 6,294 shares during the last quarter. Baker BROS. Advisors LP grew its position in Xencor by 122.2% in the first quarter. Baker BROS. Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock worth $12,070,000 after acquiring an additional 300,000 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Xencor during the 1st quarter worth $24,557,000. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Xencor by 9.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after purchasing an additional 335,881 shares in the last quarter.

Xencor Price Performance

NASDAQ XNCR opened at $18.93 on Friday. The stock has a market capitalization of $1.17 billion, a P/E ratio of -8.64 and a beta of 0.82. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.08 and a current ratio of 7.08. The business’s fifty day moving average is $21.77 and its two-hundred day moving average is $21.50. Xencor has a 1 year low of $16.49 and a 1 year high of $26.84.

Xencor (NASDAQ:XNCR) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($1.11) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.28). The company had revenue of $12.80 million for the quarter, compared to analysts’ expectations of $23.07 million. Xencor had a negative net margin of 82.23% and a negative return on equity of 20.29%. The company’s revenue for the quarter was down 32.3% on a year-over-year basis. During the same period in the prior year, the company earned ($1.02) earnings per share. On average, research analysts forecast that Xencor will post -3.5 earnings per share for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.